Efficacy
PD
DISEASE
In phase Ib, no patients had a response to combination therapy with binimetinib + panitumumab; 7 patients had stable disease for a DCR of 70% (95%CI, 34.8-93.3). In phase II, one patient in the Summary of confirmed response per local assessment.Abbreviations: CI: confidence interval; CR: complete response; DCR: disease control rate; EGFRi: epidermal growth factor receptor inhibitor; NE: not estimable; ORR: overall response rate; PD: progressive disease; PR: partial response; In phase II, the DCR was lowest in the PFS in months, per local assessment. Median PFS: phase Ib; 3.4 months (95%CI, 1.4-5.2). Phase II; all patients: 1.8 months (95%CI, 1.6-3.3); OS in months. Median OS: phase II; all patients: 5.5 months (95%CI, 3.6-7.6); 